Showing results (461-470 of 488) with videos related to
Sort By:
Pageof 49
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.Cancer Cell|January 5, 2024
Interferon-stimulated neutrophils as a predictor of immunotherapy responseMadeleine Benguigui, Tim J Cooper, Prajakta Kalkar, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2022
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)Hani Babiker, Erkut Borazanci, Vivek Subbiah, et al.Cell Reports|May 26, 2021
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFRSoma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha, et al.The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.Journal of Skin Cancer|February 1, 2013
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanomaM Klein, M Lotem, T Peretz, et al.Cell Death & Disease|May 7, 2021
Small heat-shock protein HSPB3 promotes myogenesis by regulating the lamin B receptorTatiana Tiago, Barbara Hummel, Federica F Morelli, et al.Pageof 49